NCT04654208进行中（未招募）不适用
Palbociclib Treatment Patterns in Swedish Patients With Metastatic Breast Cancer - Swedish Ibrance Registries Insights (SIRI)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer
- 入组人数
- 1,500
- 试验地点
- 1
- 主要终点
- Proportion of patients on treatment
研究概览
简要总结
The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- •One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
- •Age ≥18 years at index date
排除标准
- •There are no exclusion criteria
研究组 & 干预措施
HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)
Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)
干预措施: palbociclib (Drug)
HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant
Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)
干预措施: palbociclib (Drug)
结局指标
主要结局
Proportion of patients on treatment
时间窗: 01 January 2017 until 30 September 2020
Proportion of patients who have not discontinued treatment will be assessed at various timepoints (Time Frame: treatment start date through end of study \[assessed up to 48 months\])
次要结局
- Describe the demographic and clinical characteristics of the patient population receiving palbociclib combination treatment(01 January 2017 until 30 September 2020)
- Proportion of patients alive(01 January 2017 until 30 September 2020)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.Metastatic Breast CancerNCT04671615Pfizer559
已完成
不适用
Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort StudyHemophilia AHemophilia BNCT02740413Pfizer86
已完成
不适用
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination TherapyBreast CancerNCT04394247Pfizer242
已完成
不适用
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaMetastatic Breast CancerNCT05132101Pfizer2,758
终止
不适用
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesBreast CancerNCT04396626Pfizer975